Centre Hospitalier Intercommunal Compiegne Noyon
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The clinical research at Centre Hospitalier Intercommunal Compiegne Noyon includes studies in cardiovascular diseases, with a focus on atherosclerotic cardiovascular disease and elevated lipoprotein(a). These trials are designed to assess new approaches for reducing major heart and vascular events and improving prevention in people at increased risk.
- Testing a new therapy aimed at lowering the risk of serious cardiovascular events
- Evaluating treatment options for primary prevention of atherosclerotic cardiovascular disease
- Studying the impact of lipoprotein(a) reduction on heart outcomes
This area reflects a strong interest in better prevention strategies and more effective management of long-term cardiovascular risk.
Bacterial Infections and Mycoses
In pneumology, the site is also involved in research on bacterial infections and mycoses, particularly Mycobacterium xenopi pulmonary infection. The trial activity focuses on improving treatment effectiveness and helping patients achieve better infection control.
- Assessing whether adding a new antimicrobial therapy improves sputum conversion
- Studying treatment response in Mycobacterium xenopi pulmonary infection
- Supporting better care for difficult-to-treat respiratory infections
These studies highlight the hospital’s role in advancing care for uncommon lung infections and refining treatment strategies in pulmonary medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 34 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Intercommunal Compiegne Noyon
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Controlled Trial Comparing Azithromycin and Clarithromycin in Mycobacterium Avium Complex Pulmonary Disease Treatment | Centre Hospitalier Universitaire Amiens Picardie | Phase III | Recruiting | Feb 2018 | — |
IMP list
lock Showing 1 of 34 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 2 | Unknown | 2014-12-23 | 2024-12-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.